Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Zealand Pharma’s obesity drug candidate.

Viking enrolls around 280 participants in the phase II study evaluating the oral version of its obesity drug. Data from this ...

Roche Holding said it would pay Danish biotechnology research company Zealand Pharma up to $5.3 billion under an agreement to ...

Basel: Roche has announced that it has entered into an exclusive collaboration and licensing agreement with Zealand Pharma.

Roche and Zealand Pharma have entered into a partnership worth up to $5.3bn to advance Zealand’s mid-stage obesity candidate petrelintide.

Roche Holding agreed a collaboration and licensing deal with Zealand Pharma to co-develop a weight-loss treatment using its ...

Why it matters: Roche entered the obesity landscape with the $2.7 billion acquisition of Carmot in early 2024, giving the firm access to development-stage candidates, including CT-388 and oral ...

Roche RHHBY announced that it has entered into an exclusive collaboration and licensing agreement with Zealand Pharma for an obesity candidate. Per the terms of the agreement, both companies will ...

Roche and Zealand reason petrelintide could deliver weight loss comparable to glucagon-like peptide 1 (GLP-1) receptor agonists but without the side effects associated with GLP-1 drugs.

The two companies will work together on Zealand’s amylin analogue petrelintide as a monotherapy and in combination therapies.

Zealand Pharma (ZLDPF) and Roche (RHHBY) entered a collaboration and license agreement to co-develop and co-commercialize petrelintide as a ...